Amgen To Discuss Data Supporting Biologics License Application For ABP 501, A Biosimilar Candidate To Adalimumab

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. IBM
2. PRIM
3. META
4. KFY
5. ABBV
6. MU
7. DPZ
8. NAVN
9. DFTX
10. NVEC

Go back to Amgen To Discuss Data Supporting Biologics License Application For ABP 501, A Biosimilar Candidate To Adalimumab

Jefferies Reiterates Buy on Amgen (AMGN) Following FDA Approval of Humira Biosimilar

July 13, 2016 8:24 AM EDT

Jefferies reiterated a Buy rating and $187.00 price target on Amgen (NASDAQ: AMGN) following the FDA's approval recommendation of AMGN's Humira Biosimilar. The FDA voted unanimously, noting that the totality of the evidence demonstrates biosimilarity of ABP 501 vs. Humira.

Analyst Eun Yang commented, "While... More